Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina

• Status: Unknown status
• Trial end date: 2017-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is undertaken to determine if ticagrelor augments adenosine-induced coronary flow reserve (CFR), ameliorates clinical symptomatology and exercise tolerance in patients with MVA

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Xiangya Hospital of Central South University
• Treatments: Adenosine; Ticagrelor

Criteria

Inclusion Criteria:

For inclusion in the study subjects should fulfill the following criteria:

1. Provision of informed consent prior to any study specific procedures

2. Female or male aged 18-80 years

3. A diagnosis of stable primary MVA based on the presence of

• a history of typical effort angina,

• exercise-induced ST-segment depression>1 mm,

• normal or near-normal (coronary artery stenosis<50%) coronary angiography,

• absence vasospastic angina

• a coronary flow reserve (CFR) <2.5 in the left anterior descending coronary artery as assessed by coronary blood flow (CBF) response to adenosine at transthoracic Doppler echocardiography

• suboptimal control of symptoms on conventional anti-ischemic therapy, as indicated by the occurrence of >1 episode per week of angina

Exclusion Criteria:

ubjects should not enter the study if any of the following exclusion criteria are fulfilled:

1. concomitance with any of the cardiac condition below

• significant （>50%）coronary plaque disease

• coronary artery spasm at angiography or other evidence of vasospastic angina

• valvular or other structural heart disease

• uncontrolled hypertension

• abnormal echocardiographic examination including left ventricular hypertrophy

2. no previous consumption of the ticagrelor

3. no apparent contraindications to ticagrelor administration.

• History of Intracranial Hemorrhage

• Active Bleeding

• Severe Hepatic Impairment: AST and ALT are greater than 3 times of the upper limit. Bilirubin is greater than the upper limit.

• hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product

• severe COPD or asthma